Search Results: Treatment + Endometrial Cancer (12 results)
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Gene Abnormalities in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/244/treatment-for-advanced-or-recurrent-endometrial-cancer
Treatment
Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer
This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced cancers
This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.
Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers
https://www.facingourrisk.org/research-clinical-trials/study/232/testing-a-targeted-therapy-in-combination-with-chemotherapy-for-advanced-solid-tumors
Treatment
Treatment study for people with advanced cancers
This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
https://www.facingourrisk.org/research-clinical-trials/study/183/parp-inhibitor-niraparib-in-patients-with-inherited-or-tumor-palb2-mutations-in-advanced-solid-tumors-pavo
Treatment
Any advanced or metastatic solid tumor except ovarian or prostate
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.
Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations
https://www.facingourrisk.org/research-clinical-trials/study/249/study-of-two-drugs-in-er-andor-pr-cancers-with-pi3k-andor-pten-tumor-or-inherited-mutations
Treatment
People with advanced breast or endometrial or ovarian cancer
This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers. People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)
https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum
Treatment
Advanced endometrial cancer
This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.
Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations
https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations
Treatment
Advanced solid tumors
This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
105 results
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT ID: NCT04386993 (https://classic.clinicaltrials.gov/show/NCT04386993)
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://classic.clinicaltrials.gov/show/NCT04683653)
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT ID: NCT05139368 (https://classic.clinicaltrials.gov/show/NCT05139368)
Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT ID: NCT04458402 (https://classic.clinicaltrials.gov/show/NCT04458402)
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT ID: NCT03932409 (https://classic.clinicaltrials.gov/show/NCT03932409)
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://classic.clinicaltrials.gov/show/NCT05603910)
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT ID: NCT03955978 (https://classic.clinicaltrials.gov/show/NCT03955978)
Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://classic.clinicaltrials.gov/show/NCT04570553)
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://classic.clinicaltrials.gov/show/NCT04839614)
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT ID: NCT04586959 (https://classic.clinicaltrials.gov/show/NCT04586959)
Comparison of Nodal Staging in Endometrial Cancer
NCT ID: NCT04970368 (https://classic.clinicaltrials.gov/show/NCT04970368)
Evaluation of Quality of Life Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
NCT ID: NCT04743999 (https://classic.clinicaltrials.gov/show/NCT04743999)
Radiation and Dostarlimab in People With Endometrial Cancer After They Receive Surgery
NCT ID: NCT04774419 (https://classic.clinicaltrials.gov/show/NCT04774419)
Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://classic.clinicaltrials.gov/show/NCT03785288)
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://classic.clinicaltrials.gov/show/NCT05819892)
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT ID: NCT04514692 (https://classic.clinicaltrials.gov/show/NCT04514692)
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT ID: NCT04527900 (https://classic.clinicaltrials.gov/show/NCT04527900)
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
NCT ID: NCT03694834 (https://classic.clinicaltrials.gov/show/NCT03694834)
A Study of Patients Receiving High-Dose Rate Brachytherapy
NCT ID: NCT00924027 (https://classic.clinicaltrials.gov/show/NCT00924027)
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://classic.clinicaltrials.gov/show/NCT05950464)
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://classic.clinicaltrials.gov/show/NCT04567771)
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://classic.clinicaltrials.gov/show/NCT05691010)
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT ID: NCT04576104 (https://classic.clinicaltrials.gov/show/NCT04576104)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://classic.clinicaltrials.gov/show/NCT03968406)
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://classic.clinicaltrials.gov/show/NCT04997096)
Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://classic.clinicaltrials.gov/show/NCT05712668)
Study of ART0380 in Advanced/Metastatic Solid Tumors Patients
NCT ID: NCT05798611 (https://classic.clinicaltrials.gov/show/NCT05798611)
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT ID: NCT05646316 (https://classic.clinicaltrials.gov/show/NCT05646316)
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05761951 (https://classic.clinicaltrials.gov/show/NCT05761951)
Genetic Testing in African Americans
NCT ID: NCT05591131 (https://classic.clinicaltrials.gov/show/NCT05591131)
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://classic.clinicaltrials.gov/show/NCT05542407)
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
NCT ID: NCT03120624 (https://classic.clinicaltrials.gov/show/NCT03120624)
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT ID: NCT05036681 (https://classic.clinicaltrials.gov/show/NCT05036681)
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
NCT ID: NCT05634499 (https://classic.clinicaltrials.gov/show/NCT05634499)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://classic.clinicaltrials.gov/show/NCT05112601)
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04781088 (https://classic.clinicaltrials.gov/show/NCT04781088)
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
NCT ID: NCT04585958 (https://classic.clinicaltrials.gov/show/NCT04585958)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://classic.clinicaltrials.gov/show/NCT05039801)
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT ID: NCT05263492 (https://classic.clinicaltrials.gov/show/NCT05263492)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://classic.clinicaltrials.gov/show/NCT05691504)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)
Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://classic.clinicaltrials.gov/show/NCT04512144)
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT ID: NCT03835819 (https://classic.clinicaltrials.gov/show/NCT03835819)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://classic.clinicaltrials.gov/show/NCT05554328)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://classic.clinicaltrials.gov/show/NCT05489211)
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT ID: NCT05032040 (https://classic.clinicaltrials.gov/show/NCT05032040)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT ID: NCT04780217 (https://classic.clinicaltrials.gov/show/NCT04780217)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://classic.clinicaltrials.gov/show/NCT04469764)
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT ID: NCT05180474 (https://classic.clinicaltrials.gov/show/NCT05180474)
Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT ID: NCT04269200 (https://classic.clinicaltrials.gov/show/NCT04269200)
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT ID: NCT05538897 (https://classic.clinicaltrials.gov/show/NCT05538897)
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT ID: NCT04660929 (https://classic.clinicaltrials.gov/show/NCT04660929)
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://classic.clinicaltrials.gov/show/NCT05523440)
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT ID: NCT02628067 (https://classic.clinicaltrials.gov/show/NCT02628067)
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT ID: NCT05173987 (https://classic.clinicaltrials.gov/show/NCT05173987)
Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer
NCT ID: NCT03675893 (https://classic.clinicaltrials.gov/show/NCT03675893)
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
NCT ID: NCT05082025 (https://classic.clinicaltrials.gov/show/NCT05082025)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://classic.clinicaltrials.gov/show/NCT04851119)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT ID: NCT03752398 (https://classic.clinicaltrials.gov/show/NCT03752398)
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
NCT ID: NCT04577963 (https://classic.clinicaltrials.gov/show/NCT04577963)
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
NCT ID: NCT03008408 (https://classic.clinicaltrials.gov/show/NCT03008408)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT ID: NCT04491942 (https://classic.clinicaltrials.gov/show/NCT04491942)
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://classic.clinicaltrials.gov/show/NCT04486352)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://classic.clinicaltrials.gov/show/NCT05768139)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT ID: NCT04080284 (https://classic.clinicaltrials.gov/show/NCT04080284)
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
NCT ID: NCT05156268 (https://classic.clinicaltrials.gov/show/NCT05156268)
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT ID: NCT03917381 (https://classic.clinicaltrials.gov/show/NCT03917381)
Abemaciclib and Letrozole to Treat Endometrial Cancer
NCT ID: NCT04393285 (https://classic.clinicaltrials.gov/show/NCT04393285)
Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer
NCT ID: NCT05705505 (https://classic.clinicaltrials.gov/show/NCT05705505)
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT ID: NCT05655598 (https://classic.clinicaltrials.gov/show/NCT05655598)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://classic.clinicaltrials.gov/show/NCT03746431)
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT ID: NCT02922764 (https://classic.clinicaltrials.gov/show/NCT02922764)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT ID: NCT04278144 (https://classic.clinicaltrials.gov/show/NCT04278144)
A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://classic.clinicaltrials.gov/show/NCT05150691)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://classic.clinicaltrials.gov/show/NCT05887492)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://classic.clinicaltrials.gov/show/NCT03682289)
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
NCT ID: NCT02397083 (https://classic.clinicaltrials.gov/show/NCT02397083)
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://classic.clinicaltrials.gov/show/NCT03065062)
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://classic.clinicaltrials.gov/show/NCT04196257)
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT ID: NCT04044859 (https://classic.clinicaltrials.gov/show/NCT04044859)
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://classic.clinicaltrials.gov/show/NCT05572684)
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
NCT ID: NCT03643510 (https://classic.clinicaltrials.gov/show/NCT03643510)
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
NCT ID: NCT04586335 (https://classic.clinicaltrials.gov/show/NCT04586335)
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
NCT ID: NCT04344795 (https://classic.clinicaltrials.gov/show/NCT04344795)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT ID: NCT05169437 (https://classic.clinicaltrials.gov/show/NCT05169437)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
NCT ID: NCT02584478 (https://classic.clinicaltrials.gov/show/NCT02584478)
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT ID: NCT02611024 (https://classic.clinicaltrials.gov/show/NCT02611024)
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://classic.clinicaltrials.gov/show/NCT05252416)
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://classic.clinicaltrials.gov/show/NCT04300556)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT ID: NCT05500508 (https://classic.clinicaltrials.gov/show/NCT05500508)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT ID: NCT04262466 (https://classic.clinicaltrials.gov/show/NCT04262466)
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
NCT ID: NCT02521844 (https://classic.clinicaltrials.gov/show/NCT02521844)
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
NCT ID: NCT04008797 (https://classic.clinicaltrials.gov/show/NCT04008797)
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT ID: NCT05548296 (https://classic.clinicaltrials.gov/show/NCT05548296)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.